A probiotic-and-enzyme blend just outperformed placebo on weight, waist size and blood lipids in a randomized trial. Before you add it to your cart, read the fine print, because the details matter as much as the headline numbers.
What the Study Actually Tested
The paper, published in Frontiers in Nutrition in 2026 (Rathi et al., DOI 10.3389/fnut.2026.1956865), tested a supplement called SlimSEB. It is a multi-ingredient blend containing:
- Probiotics (1.5 billion CFU)
- Digestive enzymes, including one called SucroSEB, which the maker says converts dietary sugars into prebiotic fibre
- Mulberry leaf extract
- Green tea
- Cinnamon powder
- Chromium picolinate
The design was prospective, randomized, double-blind, parallel-group and placebo-controlled. Eighty-seven adults at risk of type 2 diabetes took either SlimSEB or placebo daily for 84 days (12 weeks). Of these, 43 were classed as overweight and 44 as obese. The trial was registered as CTRI/2023/11/059798.
The Headline Numbers
Compared with placebo, SlimSEB produced statistically significant extra reductions (adjusted least-squares mean differences):
- Body weight: -2.60 kg in the overweight group (p=0.0045) and -4.51 kg in the obese group (p<0.0001)
- BMI: -0.92 and -1.80 kg/m²
- Waist circumference: -3.86 cm in overweight (p=0.0169) and -11.03 cm in obese (p=0.0014)
The waist figure in the obese group is the most striking result. An 11 cm difference in 12 weeks is large for a supplement, which is a reason for curiosity and also for caution.
Metabolic Markers Moved Too
The abstract also reports improvements in blood sugar markers: fasting plasma glucose down 0.45 mmol/L in both groups, HbA1c down 0.65% and 0.67%, and HOMA-IR (an insulin resistance estimate) down 0.47 and 0.69. Trade coverage of the study put the HOMA-IR drops at 21.5% versus 9.0% on placebo in the overweight group, and 24.8% versus 4.3% in the obese group.
Cholesterol showed the biggest contrast:
- Total cholesterol fell 14.21% and 16% with SlimSEB. With placebo it fell 3.85% in the overweight group and rose 8.65% in the obese group.
- LDL fell 11.61% and 14.63% with SlimSEB. With placebo it fell 0.88% in the overweight group and rose 13.39% in the obese group.
- C-reactive protein (CRP), an inflammation marker, fell 13.6% and 17.3%, but the between-group difference was significant only in obese participants.
Note that the placebo group's lipids got worse in the obese subgroup. That makes the comparison look more dramatic than the supplement's own improvement would suggest.
Safety Profile
There were eight mild adverse events, none judged related to the product, and no serious adverse events. That is reassuring, but a trial of 87 people over 12 weeks cannot rule out rarer or longer-term problems.
Here's the Catch
Several limitations keep this from being a buy-it-now verdict:
- Industry link. The product was supplied by Specialty Enzymes and Probiotics (USA), its maker. That likely means industry involvement, which doesn't invalidate the results but calls for independent replication.
- Small and single-country. It was one trial in India with 87 participants split into two subgroups. Results may not carry over to other diets, ethnicities or settings.
- Short duration. Twelve weeks says nothing about whether weight stays off or whether benefits persist.
- A blend, not a single compound. With probiotics, enzymes, mulberry, green tea, cinnamon and chromium all in one product, no single ingredient can be credited for the effect.
- Unknown dose details. The exact daily dose of the finished product isn't given in the material available here, so I won't guess it.
How Big Is This, Really?
A 2.6 to 4.5 kg placebo-adjusted loss is modest. Prescription GLP-1 drugs sit on a different scale: in the pivotal STEP 1 trial, semaglutide produced average weight loss of roughly 15% of body weight over 68 weeks. SlimSEB is not in that league, and the data don't suggest it is a substitute. It may be a small, adjunct-level effect worth further study.
Practical Takeaways
Dose and timing: The trial used a daily regimen for 84 days, but the specific serving size and timing aren't available in the source material I reviewed. Follow the product label and check the full paper before relying on any specific protocol. The one number I can confirm is the probiotic content of 1.5 billion CFU.
Who it might suit: The evidence applies to overweight or obese adults at risk of type 2 diabetes. It doesn't cover people with established diabetes, children, or people who are already lean.
Who should skip it or ask a clinician first (general cautions, not findings from this paper):
- People on diabetes medication, since the blend contains ingredients associated with glucose lowering
- Pregnant or breastfeeding women
- Immunocompromised people, because of the live probiotics
- Anyone sensitive to caffeine or green tea extracts
- Anyone expecting dramatic, GLP-1-style weight loss
Bottom line: This is a promising but preliminary, manufacturer-linked result. Diet quality, activity and sleep remain the foundation, and a larger independent trial would tell us whether this blend deserves a place beside them.